title: [Use of somatostatin analogues in the pancreonecrosis therapy (kliniko-experimental research)].
abstract: The article is devoted to the study and optimization of therapeutic strategy in pancreatic necrosis. We studied the effectiveness of clinical application of human somatostatin analog - octreotide in different dosages. Submitted investigationconsists of experimental and clinical parts.
  
  
  METHODS
  Experimentalmodel of acute destructive pancreatitis onrats of Wistar line with weight of 300±30 gwas reproduced.There were 5 animal groups (one control group and four experimental groups). Experimental animals received oktreotidin different doses. In 2 days there were estimated the blood biochemistryand histopathologic features of liver and pancreas of operated animals. In clinical part there were formed two groups of patients out of selected case histories by a principle of similarity of complex therapy differing in oktreotid doses, namely: 1) pancreatonecrosis patients estimated of 3 to 8 points by Ranson scale in whose treatment regimen oktreotid 300 mkg/day (n=70) dose was included; 2) pancreatonecrosispatients estimated of 3 to 8 points by Ransonin whose treatment regimenoktreoid1200 mkg/day (n=38) was included. There were compared indices of lethal outcomes, average bed-days, and dynamics of laboratory findings, number and volume of surgical procedures.
  
  
  CONCLUSIONS
  Dose-related effect of a synthetic analogue of somatostatin, acetateoktreotid, was proved. Introduction in complex therapy of pancreatonecrosisthe highest possible authorized doses of oktreotid (1200 mkg/day) is conducive to more favorable course of illness, dynamic reduction of amilazemia, decrease of lethal outcomes and total bed-day, and also, reduction of initial and repeated operative procedures.
authors.affiliation: Federal Clinical Center of High Medical Technologies, FMBA of Russia.
authors.forename: K V
authors.initials: KV
authors.lastname: Agapov
authors.affiliation: Federal Clinical Center of High Medical Technologies, FMBA of Russia.
authors.forename: A A
authors.initials: AA
authors.lastname: Shutov
authors.affiliation: Pirogov Russian National Research University, Moscow, Russia.
authors.forename: M D
authors.initials: MD
authors.lastname: Polyvoda
authors.affiliation: Federal Clinical Center of High Medical Technologies, FMBA of Russia.
authors.forename: N B
authors.initials: NB
authors.lastname: Pavlov
authors.affiliation: Federal Clinical Center of High Medical Technologies, FMBA of Russia.
authors.forename: M G
authors.initials: MG
authors.lastname: Bagdatieva
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D009336:Necrosis; D015282:Octreotide / Q000627:therapeutic use*; D010179:Pancreas / Q000187:drug effects / Q000473:pathology*; D010195:Pancreatitis / Q000188:drug therapy*; D051381:Rats; D017208:Rats, Wistar; D013004:Somatostatin / Q000031:analogs & derivatives*
chemical_list: D005765:Gastrointestinal Agents; D013004:Somatostatin; D015282:Octreotide